Adeno-associated virus-mediated cancer gene therapy: Current status

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 347-356

  Luo, Jingfeng ^a   Luo, Yuxuan ^b   Sun, Jihong ^a   Zhou, Yurong ^a   Zhang, Yajing ^a   Yang, Xiaoming ^a,c  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHUJI PEOPLE S HOSPITAL OF ZHEJIANG PROVINCE   (China)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Adeno associated virus; Cancer; Cancer gene therapy; Gene vehicle

Indexed keywords

BETA INTERFERON; BLOOD CLOTTING FACTOR 9; CHEMOKINE RECEPTOR CCR4; INTERLEUKIN 12; INTERLEUKIN 15; MICRORNA; PARVOVIRUS VECTOR; PROGRAMMED DEATH 1 RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROTEINASE ACTIVATED RECEPTOR 4;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CHOROIDEREMIA; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENE TRANSFER; GLIOBLASTOMA; HEMOPHILIA B; HUMAN; IMMUNITY; IMMUNOGENICITY; IMMUNOTHERAPY; LEBER CONGENITAL AMAUROSIS; LIVER CELL CARCINOMA; LYMPHOMA; NASOPHARYNX CARCINOMA; NONHUMAN; PARKINSON DISEASE; PROSTATE CANCER; RETINOBLASTOMA; RNA INTERFERENCE; SHORT SURVEY; TRANSGENE; UTERINE CERVIX CANCER; VIRAL GENE DELIVERY SYSTEM; VIRAL TROPISM; VIRUS MORPHOLOGY; VIRUS NEUTRALIZATION; ANIMAL; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETICS; NEOPLASMS; THERAPEUTIC USE; TUMOR GENE;

ADENO-ASSOCIATED VIRUS;

ANIMALS; DEPENDOVIRUS; GENES, NEOPLASM; GENETIC THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS;

EID: 84919430043     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.10.045     Document Type: Review

References (122)

1. Furman R.R., Cheng S., Lu P., Setty M., Perez A.R., Guo A., et al. Ibrutinib resistance in chronic lymphocytic leukemia. N. Engl. J. Med 2014, 370:2352-2354.
2. Thomas R.K. Overcoming drug resistance in ALK-rearranged lung cancer. N. Engl. J. Med 2014, 370:1250-1251.
3. Su C.H., Wu Y.J., Wang H.H., Yeh H.I. Nonviral gene therapy targeting cardiovascular system. Am. J. Physiol 2012, 303:H629-H638.
4. Petrs-Silva H., Linden R. Advances in recombinant adeno-associated viral vectors for gene delivery. Curr. Gene Ther 2013, 13:335-345.
5. Atchison R.W., Casto B.C., Hammon W.M. Adenovirus-associated defective virus particles. Science 1965, 149:754-756.
6. Rutledge E.A., Halbert C.L., Russell D.W. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol 1998, 72:309-319.
7. Xie Q., Bu W., Bhatia S., Hare J., Somasundaram T., Azzi A., et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:10405-10410.
8. Gao G., Vandenberghe L.H., Alvira M.R., Lu Y., Calcedo R., Zhou X., et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol 2004, 78:6381-6388.
9. Hauck B., Xiao W. Characterization of tissue tropism determinants of adeno-associated virus type 1. J. Virol 2003, 77:2768-2774.
10. Tsai L.K., Chen C.L., Ting C.H., Lin-Chao S., Hwu W.L., Dodge J.C., et al. Systemic administration of a recombinant AAV1 vector encoding IGF-1 improves disease manifestations in SMA mice. Mol. Ther 2014, 22:1450-1459.
11. Joniec-Maciejak I., Ciesielska A., Wawer A., Sznejder-Pacholek A., Schwenkgrub J., Cudna A., et al. The influence of AAV2-mediated gene transfer of human IL-10 on neurodegeneration and immune response in a murine model of Parkinson's disease. Pharmacol. Rep 2014, 66:660-669.
12. Ahn M., Bajsarowicz K., Oehler A., Lemus A., Bankiewicz K., DeArmond S.J. Convection-enhanced delivery of AAV2-PrPshRNA in prion-infected mice. PLoS ONE 2014, 9:e98496.
13. Xu H., Zhang L., Gu L., Lu L., Gao G., Li W., et al. Subretinal delivery of AAV2-mediated human erythropoietin gene is protective and safe in experimental diabetic retinopathy. Invest. Ophthalmol. Vis. Sci 2014, 55:1519-1530.
14. Liu Y., Okada T., Sheykholeslami K., Shimazaki K., Nomoto T., Muramatsu S., et al. Specific and efficient transduction of cochlear inner hair cells with recombinant adeno-associated virus type 3 vector. Mol. Ther 2005, 12:725-733.
15. Glushakova L.G., Lisankie M.J., Eruslanov E.B., Ojano-Dirain C., Zolotukhin I., Liu C., et al. AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab 2009, 98:289-299.
16. Shen S., Troupes A.N., Pulicherla N., Asokan A. Multiple roles for sialylated glycans in determining the cardiopulmonary tropism of adeno-associated virus 4. J. Virol 2013, 87:13206-13213.
17. Zabner J., Seiler M., Walters R., Kotin R.M., Fulgeras W., Davidson B.L., et al. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J. Virol 2000, 74:3852-3858.
18. Halbert C.L., Allen J.M., Miller A.D. Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J. Virol 2001, 75:6615-6624.
19. Lebherz C., Maguire A., Tang W., Bennett J., Wilson J.M. Novel AAV serotypes for improved ocular gene transfer. J. Gene Med 2008, 10:375-382.
20. Zincarelli C., Soltys S., Rengo G., Rabinowitz J.E. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther 2008, 16:1073-1080.
21. Igarashi T., Miyake N., Fujimoto C., Yaguchi C., Iijima O., Shimada T., et al. Adeno-associated virus type 8 vector-mediated expression of siRNA targeting vascular endothelial growth factor efficiently inhibits neovascularization in a murine choroidal neovascularization model. Mol. Vis 2014, 20:488-496.
22. Ruzo A., Marco S., Garcia M., Villacampa P., Ribera A., Ayuso E., et al. Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer. Hum. Gene Ther 2012, 23:1237-1246.
23. Mori S., Wang L., Takeuchi T., Kanda T. Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virol 2004, 330:375-383.
24. Sondhi D., Hackett N.R., Peterson D.A., Stratton J., Baad M., Travis K.M., et al. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol. Ther 2007, 15:481-491.
25. Schmidt M., Voutetakis A., Afione S., Zheng C., Mandikian D., Chiorini J.A. Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol 2008, 82:1399-1406.
26. Zhang H., Yang B., Mu X., Ahmed S.S., Su Q., He R., et al. Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol. Ther 2011, 19:1440-1448.
27. Dong J.Y., Fan P.D., Frizzell R.A. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum. Gene Ther 1996, 7:2101-2112.
28. Sun J.Y., Anand-Jawa V., Chatterjee S., Wong K.K. Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther 2003, 10:964-976.
29. McCarty D.M., Monahan P.E., Samulski R.J. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 2001, 8:1248-1254.
30. Kwon I., Schaffer D.V. Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Pharm. Res 2008, 25:489-499.
31. Tratschin J.D., West M.H., Sandbank T., Carter B.J. A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase. Mol. Cell. Biol 1984, 4:2072-2081.
32. Flotte T., Carter B., Conrad C., Guggino W., Reynolds T., Rosenstein B., et al. A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum. Gene Ther 1996, 7:1145-1159.
33. Smith B.K., Collins S.W., Conlon T.J., Mah C.S., Lawson L.A., Martin A.D., et al. II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. Hum. Gene Ther 2013, 24:630-640.
34. Mueller C., Chulay J.D., Trapnell B.C., Humphries M., Carey B., Sandhaus R.A., et al. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J. Clin. Invest 2013, 123:5310-5318.
35. Flotte T.R., Trapnell B.C., Humphries M., Carey B., Calcedo R., Rouhani F., et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: interim results. Hum. Gene Ther 2011, 22:1239-1247.
36. Mendell J.R., Rodino-Klapac L.R., Rosales X.Q., Coley B.D., Galloway G., Lewis S., et al. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann. Neurol 2010, 68:629-638.
37. Ferreira V., Twisk J., Kwikkers K., Aronica E., Brisson D., Methot J., et al. Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy. Hum. Gene Ther 2014, 25:180-188.
38. Mueller C., Braag S.A., Martino A.T., Tang Q., Campbell-Thompson M., Flotte T.R. The pros and cons of immunomodulatory IL-10 gene therapy with recombinant AAV in a Cftr-/- -dependent allergy mouse model. Gene Ther 2009, 16:172-183.
39. Yang J., Pattanayak A., Song M., Kou J., Taguchi H., Paul S., et al. Muscle-directed anti-Abeta single-chain antibody delivery via AAV1 reduces cerebral Abeta load in an Alzheimer's disease mouse model. J. Mol. Neurosci 2013, 49:277-288.
40. MacLaren R.E., Groppe M., Barnard A.R., Cottriall C.L., Tolmachova T., Seymour L., et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet 2014, 383:1129-1137.
41. Ashtari M., Cyckowski L.L., Monroe J.F., Marshall K.A., Chung D.C., Auricchio A., et al. The human visual cortex responds to gene therapy-mediated recovery of retinal function. J. Clin. Invest 2011, 121:2160-2168.
42. Muramatsu S., Fujimoto K., Kato S., Mizukami H., Asari S., Ikeguchi K., et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol. Ther 2010, 18:1731-1735.
43. Benraiss A., Toner M.J., Xu Q., Bruel-Jungerman E., Rogers E.H., Wang F., et al. Sustained mobilization of endogenous neural progenitors delays disease progression in a transgenic model of Huntington's disease. Cell Stem Cell 2013, 12:787-799.
44. Dodge J.C., Treleaven C.M., Fidler J.A., Hester M., Haidet A., Handy C., et al. AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol. Ther 2010, 18:2075-2084.
45. Lheriteau E., Petit L., Weber M., Le Meur G., Deschamps J.Y., Libeau L., et al. Successful gene therapy in the RPGRIP1-deficient dog: a large model of cone-rod dystrophy. Mol. Ther 2014, 22:265-277.
46. Popiel H.A., Takeuchi T., Fujita H., Yamamoto K., Ito C., Yamane H., et al. Hsp40 gene therapy exerts therapeutic effects on polyglutamine disease mice via a non-cell autonomous mechanism. PLoS ONE 2012, 7:e51069.
47. Weber C., Neacsu I., Krautz B., Schlegel P., Sauer S., Raake P., et al. Therapeutic safety of high myocardial expression levels of the molecular inotrope S100A1 in a preclinical heart failure model. Gene Ther 2014, 21:131-138.
48. Evans J.M., Navarro S., Doki T., Stewart J.M., Mitsuhashi N., Kearns-Jonker M. Gene transfer of heme oxygenase-1 using an adeno-associated virus serotype 6 vector prolongs cardiac allograft survival. J. Transplant 2012, 2012:740653.
49. Luo X., Hall G., Li S., Bird A., Lavin P.J., Winn M.P., et al. Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector. Mol. Ther 2011, 19:1961-1970.
50. Nathwani A.C., Tuddenham E.G., Rangarajan S., Rosales C., McIntosh J., Linch D.C., et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med 2011, 365:2357-2365.
51. Anisimov A., Alitalo A., Korpisalo P., Soronen J., Kaijalainen S., Leppanen V.M., et al. Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle. Circ. Res 2009, 104:1302-1312.
52. Kou J., Yang J., Lim J.E., Pattanayak A., Song M., Planque S., et al. Catalytic immunoglobulin gene delivery in a mouse model of Alzheimer's disease: prophylactic and therapeutic applications. Mol. Neurobiol 2014, Epub ahead of print. 10.1007/s12035-014-8691-z.
53. Chaanine A.H., Nonnenmacher M., Kohlbrenner E., Jin D., Kovacic J.C., Akar F.G., et al. Effect of bortezomib on the efficacy of AAV9.SERCA2a treatment to preserve cardiac function in a rat pressure-overload model of heart failure. Gene Ther 2014, 21:379-386.
54. Ganesan J., Ramanujam D., Sassi Y., Ahles A., Jentzsch C., Werfel S., et al. MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation 2013, 127:2097-2106.
55. Timiri Shanmugam P.S., Dayton R.D., Palaniyandi S., Abreo F., Caldito G., Klein R.L., et al. Recombinant AAV9-TLK1B administration ameliorates fractionated radiation-induced xerostomia. Hum. Gene Ther 2013, 24:604-612.
56. Perdomini M., Belbellaa B., Monassier L., Reutenauer L., Messaddeq N., Cartier N., et al. Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia. Nat. Med 2014, 20:542-547. 10.1038/nm.3510.
57. Sondhi D., Scott E.C., Chen A., Hackett N.R., Wong A.M., Kubiak A., et al. Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus Serotype rh.10 vector expressing the human CLN3 gene. Hum. Gene Ther 2014, 25:223-239.
58. Kojima Y., Honda K., Hamada H., Kobayashi N. Oncolytic gene therapy combined with double suicide genes for human bile duct cancer in nude mouse models. J. Surg. Res 2009, 157:e63-e70.
59. Pan J.G., Zhou X., Luo R., Han R.F. The adeno-associated virus-mediated HSV-TK/GCV suicide system: a potential strategy for the treatment of bladder carcinoma. Med. Oncol 2012, 29:1938-1947.
60. Kim J.Y., Kim J.H., Khim M., Lee H.S., Jung J.H., Moon D.H., et al. Persistent anti-tumor effects via recombinant adeno-associated virus encoding herpes thymidine kinase gene monitored by PET-imaging. Oncol. Rep 2011, 25:1263-1269.
61. Trepel M., Stoneham C.A., Eleftherohorinou H., Mazarakis N.D., Pasqualini R., Arap W., et al. A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transfer. Mol. Cancer Ther 2009, 8:2383-2391.
62. Denny W.A. Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy). J. Biomed. Biotechnol 2003, 2003:48-70.
63. Huang Q., Liu X.Z., Kang C.S., Wang G.X., Zhong Y., Pu P.Y. The anti-glioma effect of suicide gene therapy using BMSC expressing HSV/TK combined with overexpression of Cx43 in glioma cells. Cancer Gene Ther 2010, 17:192-202.
64. Sanson M., Marcaud V., Robin E., Valery C., Sturtz F., Zalc B. Connexin 43-mediated bystander effect in two rat glioma cell models. Cancer Gene Ther 2002, 9:149-155.
65. Baranova A., Ivanov D., Petrash N., Pestova A., Skoblov M., Kelmanson I., et al. The mammalian pannexin family is homologous to the invertebrate innexin gap junction proteins. Genomics 2004, 83:706-716.
66. Lai C.P., Bechberger J.F., Thompson R.J., MacVicar B.A., Bruzzone R., Naus C.C. Tumor-suppressive effects of pannexin 1 in C6 glioma cells. Cancer Res 2007, 67:1545-1554.
67. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med 1971, 285:1182-1186.
68. Lu L., Luo S.T., Shi H.S., Li M., Zhang H.L., He S.S., et al. AAV2-mediated gene transfer of VEGF-Trap with potent suppression of primary breast tumor growth and spontaneous pulmonary metastases by long-term expression. Oncol. Rep 2012, 28:1332-1338.
69. Wu Q.J., Gong C.Y., Luo S.T., Zhang D.M., Zhang S., Shi H.S., et al. AAV-mediated human PEDF inhibits tumor growth and metastasis in murine colorectal peritoneal carcinomatosis model. BMC Cancer 2012, 12:129.
70. He S.S., Shi H.S., Yin T., Li Y.X., Luo S.T., Wu Q.J., et al. AAV-mediated gene transfer of human pigment epithelium-derived factor inhibits Lewis lung carcinoma growth in mice. Oncol. Rep 2012, 27:1142-1148.
71. Bui Nguyen T.M., Subramanian I.V., Xiao X., Nguyen P., Ramakrishnan S. Adeno-associated virus-mediated delivery of kringle 5 of human plasminogen inhibits orthotopic growth of ovarian cancer. Gene Ther 2010, 17:606-615.
72. Tse L.Y., Sun X., Jiang H., Dong X., Fung P.W., Farzaneh F., et al. Adeno-associated virus-mediated expression of kallistatin suppresses local and remote hepatocellular carcinomas. J. Gene Med 2008, 10:508-517.
73. Buhles A., Collins S.A., van Pijkeren J.P., Rajendran S., Miles M., O'Sullivan G.C., et al. Anti-metastatic effects of viral and non-viral mediated Nk4 delivery to tumours. Genet. Vaccines Ther 2009, 7:5.
74. Mahadevan M., Liu Y., You C., Luo R., You H., Mehta J.L., et al. Generation of robust cytotoxic T lymphocytes against prostate specific antigen by transduction of dendritic cells using protein and recombinant adeno-associated virus. Cancer Immunol. Immunother 2007, 56:1615-1624.
75. Chiu T.L., Peng C.W., Wang M.J. Enhanced anti-glioblastoma activity of microglia by AAV2-mediated IL-12 through TRAIL and phagocytosis in vitro. Oncol. Rep 2011, 25:1373-1380.
76. Yiang G.T., Harn H.J., Yu Y.L., Hu S.C., Hung Y.T., Hsieh C.J., et al. Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice. J. Biomed. Sci 2009, 16:47.
77. Yiang G.T., Chou P.L., Tsai H.F., Chen L.A., Chang W.J., Yu Y.L., et al. Immunotherapy for SV40 T/t antigen-induced breast cancer by recombinant adeno-associated virus serotype 2 carrying interleukin-15 in mice. Int. J. Mol. Med 2012, 29:809-814.
78. Han T., Abdel-Motal U.M., Chang D.K., Sui J., Muvaffak A., Campbell J., et al. Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma. PLoS ONE 2012, 7:e44455.
79. Meijer D.H., Maguire C.A., LeRoy S.G., Sena-Esteves M. Controlling brain tumor growth by intraventricular administration of an AAV vector encoding IFN-beta. Cancer Gene Ther 2009, 16:664-671.
80. Liu X., Lu J., He M.L., Li Z., Zhang B., Zhou L.H., et al. Antitumor effects of interferon-alpha on cell growth and metastasis in human nasopharyngeal carcinoma. Curr. Cancer Drug Targets 2012, 12:561-570.
81. Nieto K., Kern A., Leuchs B., Gissmann L., Muller M., Kleinschmidt J.A. Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors. Antiviral Ther 2009, 14:1125-1137.
82. Pan J., Zhang Q., Zhou J., Ma D., Xiao X., Wang D.W. Recombinant adeno-associated virus encoding Epstein-Barr virus latent membrane proteins fused with heat shock protein as a potential vaccine for nasopharyngeal carcinoma. Mol. Cancer Ther 2009, 8:2754-2761.
83. Li R., Hu H., Ma H., Chen L., Zhou B., Liu Y., et al. The anti-tumor effect and increased tregs infiltration mediated by rAAV-SLC vector. Mol. Biol. Rep 2013, 40:5615-5623.
84. Elhag O.A., Hu X.J., Wen-Ying Z., Li X., Yuan Y.Z., Deng L.F., et al. Reconstructed adeno-associated virus with the extracellular domain of murine PD-1 induces antitumor immunity. Asian Pac. J. Cancer Prev 2012, 13:4031-4036.
85. Sun H., Liu Y., Bu D., Liu X., Norris J.S., Xiao S. Efficient growth suppression and apoptosis in human laryngeal carcinoma cell line HEP-2 induced by an adeno-associated virus expressing human FAS ligand. Head Neck 2012, 34:1628-1633.
86. He Z.H., Lei Z., Zhen Y., Gong W., Huang B., Yuan Y., et al. Adeno-associated virus-mediated expression of recombinant CBD-HepII polypeptide of human fibronectin inhibits metastasis of breast cancer. Breast Cancer Res. Treat 2014, 143:33-45.
87. Qin T.J., Ma W., Liu S.X., Yang G.X., Wang Q.Y., Zhao X.H. Secretory expression of Par-4 SAC-HA2TAT following adeno-associated virus-mediated gene transfer induces apoptosis in HepG2 cells. Mol. Med. Rep 2010, 3:749-757.
88. Lv F., Qiu Y., Zhang Y., Liu S., Shi J., Liu Y., et al. Adeno-associated virus-mediated anti-DR5 chimeric antibody expression suppresses human tumor growth in nude mice. Cancer Lett 2011, 302:119-127.
89. Xiaojiang T., Jinsong Z., Jiansheng W., Chengen P., Guangxiao Y., Quanying W. Adeno-associated virus harboring fusion gene NT4-ant-shepherdin induce cell death in human lung cancer cells. Cancer Invest 2010, 28:465-471.
90. Ng S.S., Gao Y., Chau D.H., Li G.H., Lai L.H., Huang P.T., et al. A novel glioblastoma cancer gene therapy using AAV-mediated long-term expression of human TERT C-terminal polypeptide. Cancer Gene Ther 2007, 14:561-572.
91. Sun A., Tang J., Terranova P.F., Zhang X., Thrasher J.B., Li B. Adeno-associated virus-delivered short hairpin-structured RNA for androgen receptor gene silencing induces tumor eradication of prostate cancer xenografts in nude mice: a preclinical study. Int. J. Cancer 2010, 126:764-774.
92. Kota J., Chivukula R.R., O'Donnell K.A., Wentzel E.A., Montgomery C.L., Hwang H.W., et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137:1005-1017.
93. Chen J., Liu X., Chen X., Guo Z., Liu J., Hao J., et al. Real-time monitoring of miRNA function in pancreatic cell lines using recombinant AAV-based miRNA Asensors. PLoS ONE 2013, 8:e66315.
94. Ruan Q., Xi L., Boye S.L., Han S., Chen Z.J., Hauswirth W.W., et al. Development of an anti-angiogenic therapeutic model combining scAAV2-delivered siRNAs and noninvasive photoacoustic imaging of tumor vasculature development. Cancer Lett 2013, 332:120-129.
95. Zhang K., Jiao X., Liu X., Zhang B., Wang J., Wang Q., et al. Knockdown of snail sensitizes pancreatic cancer cells to chemotherapeutic agents and irradiation. Int. J. Mol. Sci 2010, 11:4891-4892.
96. Zhang Y., Ma H., Zhang J., Liu S., Liu Y., Zheng D. AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice. Life Sci 2008, 82:1154-1161.
97. Wang Y., Huang F., Cai H., Zhong S., Liu X., Tan W.S. Potent antitumor effect of TRAIL mediated by a novel adeno-associated viral vector targeting to telomerase activity for human hepatocellular carcinoma. J. Gene Med 2008, 10:518-526.
98. He L.F., Wang Y.G., Xiao T., Zhang K.J., Li G.C., Gu J.F., et al. Suppression of cancer growth in mice by adeno-associated virus vector-mediated IFN-beta expression driven by hTERT promoter. Cancer Lett 2009, 286:196-205.
99. Ma H., Liu Y., Liu S., Xu R., Zheng D. Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice. Hepatology 2005, 42:1355-1363.
100. Lee H.S., Kim J.Y., Lee W.I., Kim S.J., Ko M.J., Jeong S., et al. Acquisition of selective antitumoral effects of recombinant adeno-associated virus by genetically inserting tumor-targeting peptides into capsid proteins. Oncol. Lett 2011, 2:1113-1119.
101. Yuan L., Zhao H., Zhang L., Liu X. The efficacy of combination therapy using adeno-associated virus-mediated co-expression of apoptin and interleukin-24 on hepatocellular carcinoma. Tumour Biol 2013, 34:3027-3034.
102. Pan J.G., Zhou X., Zeng G.W., Han R.F. Potent antitumour activity of the combination of HSV-TK and endostatin armed oncolytic adeno-associated virus for bladder cancer in vitro and in vivo. J. Surg. Oncol 2012, 105:249-257.
103. Pan J.G., Luo R.Q., Zhou X., Han R.F., Zeng G.W. Potent antitumor activity of the combination of HSV-TK and endostatin by adeno-associated virus vector for bladder cancer in vivo. Clin. Lab 2013, 59:1147-1158.
104. Wang Y., Huang F., Cai H., Wu Y., He G., Tan W.S. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol 2010, 136:1827-1837.
105. Jiang M., Liu Z., Xiang Y., Ma H., Liu S., Liu Y., et al. Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma. BMC Cancer 2011, 11:54.
106. Subramanian I.V., Devineni S., Ghebre R., Ghosh G., Joshi H.P., Jing Y., et al. AAV-P125A-endostatin and paclitaxel treatment increases endoreduplication in endothelial cells and inhibits metastasis of breast cancer. Gene Ther 2011, 18:145-154.
107. Subramanian I.V., Bui Nguyen T.M., Truskinovsky A.M., Tolar J., Blazar B.R., Ramakrishnan S. Adeno-associated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival. Cancer Res 2006, 66:4319-4328.
108. Hamner J.B., Sims T.L., Cutshaw A., Dickson P.V., Rosati S., McGee M., et al. The efficacy of combination therapy using adeno-associated virus - interferon beta and trichostatin A in vitro and in a murine model of neuroblastoma. J. Pediatr. Surg 2008, 43:177-182. discussion 182-173.
109. Xue Z., Sun P.H., Zhu L.M., Jiang S.H., Qiao M.M., Chi A.L., et al. Adeno-associated virus-mediated survivin mutant Thr34Ala cooperates with oxaliplatin to inhibit tumor growth and angiogenesis in colon cancer. Oncol. Rep 2011, 25:1039-1046.
110. Kanazawa T., Mizukami H., Okada T., Hanazono Y., Kume A., Nishino H., et al. Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice. Gene Ther 2003, 10:51-58.
111. Zhou S.J., Li S.W., Wang J.J., Liu Z.J., Yin G.B., Gong J.P., et al. High-intensity focused ultrasound combined with herpes simplex virus thymidine kinase gene-loaded ultrasound-targeted microbubbles improved the survival of rabbits with VX(2) liver tumor. J. Gene Med 2012, 14:570-579.
112. Kay M.A., Manno C.S., Ragni M.V., Larson P.J., Couto L.B., McClelland A., et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet 2000, 24:257-261.
113. Manno C.S., Pierce G.F., Arruda V.R., Glader B., Ragni M., Rasko J.J., et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med 2006, 12:342-347.
114. Manno C.S., Chew A.J., Hutchison S., Larson P.J., Herzog R.W., Arruda V.R., et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003, 101:2963-2972.
115. Buchlis G., Podsakoff G.M., Radu A., Hawk S.M., Flake A.W., Mingozzi F., et al. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood 2012, 119:3038-3041.
116. Brantly M.L., Chulay J.D., Wang L., Mueller C., Humphries M., Spencer L.T., et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:16363-16368.
117. Marks W.J., Ostrem J.L., Verhagen L., Starr P.A., Larson P.S., Bakay R.A., et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 2008, 7:400-408.
118. Bartus R.T., Baumann T.L., Siffert J., Herzog C.D., Alterman R., Boulis N., et al. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 2013, 80:1698-1701.
119. Mittermeyer G., Christine C.W., Rosenbluth K.H., Baker S.L., Starr P., Larson P., et al. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum. Gene Ther 2012, 23:377-381.
120. Jacobson S.G., Cideciyan A.V., Ratnakaram R., Heon E., Schwartz S.B., Roman A.J., et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch. Ophthalmol 2012, 130:9-24.
121. Di L., Zhu Y., Jia J., Yu J., Song G., Zhang J., et al. Clinical safety of induced CTL infusion through recombinant adeno-associated virus-transfected dendritic cell vaccination in Chinese cancer patients. Clin. Transl. Oncol 2012, 14:675-681.
122. Mease P.J., Hobbs K., Chalmers A., El-Gabalawy H., Bookman A., Keystone E., et al. Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study. Ann. Rheum. Dis 2009, 68:1247-1254.